Trials / Completed
CompletedNCT04086719
An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.
An Open-Label, Single Sequence, Crossover Study to Investigate the Effects of OCT1 Inhibition Utilizing Pyrimethamine on Pharmacokinetics of BMS-986165 in Healthy Male Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Study of what the body does to drug BMS-986165 when it is taken together with pyrimethamine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Oral administration of tablet BMS- 986165 |
| DRUG | Pyrimethamine | Oral administration of Pyrimethamine in combination with BMS-986185 |
Timeline
- Start date
- 2019-09-12
- Primary completion
- 2019-10-29
- Completion
- 2019-10-29
- First posted
- 2019-09-12
- Last updated
- 2020-08-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04086719. Inclusion in this directory is not an endorsement.